SAN FRANCISCO, CA – CanWell Pharma is pleased to announce its participation in the 44th Annual J.P. Morgan Healthcare Conference (JPM 2026), taking place from January 12–15, 2026, at the Westin St. Francis Hotel in San Francisco.
As one of the world’s most prestigious healthcare investment symposiums, JPM 2026 will host over 8,000 global leaders, including senior executives from premier biotechnology firms and top-tier institutional investors. This year’s conference is set to highlight pivotal advancements in AI-driven drug discovery, cell and gene therapies (CGT), and the evolving landscape of global mergers and acquisitions (M&A).
CanWell Pharma intends to utilize this premier platform to engage with international partners and the investment community. The company will showcase its latest technological milestones, innovative pipeline, and long-term commitment to advancing global healthcare through strategic collaboration.
“Our participation in JPM 2026 represents a significant step in our international trajectory,” the company stated. “We look forward to fostering the partnerships necessary to accelerate the delivery of transformative therapies to patients worldwide.”